Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301529 | 0.85 | SCN10A (0.63) | ABL1SCN10ASCN2ALMNAMAPT | |
| SCHEMBL31301643 | 0.85 | ABL1 (0.56) | ABL1SCN10ASCN2ALMNAMAPT | |
| SCHEMBL31301597 | 0.81 | SCN10A (0.52) | ABL1SCN10ASCN2ALMNAMAPT | |
| SCHEMBL31301343 | 0.80 | KCNQ3 (0.66) | ABL1SCN10ASCN2ALMNAMAPT | |
| SCHEMBL31301458 | 0.79 | SCN10A (0.54) | ABL1MCHR1SCN10ASCN2ALMNA | |
| SCHEMBL31301446 | 0.79 | DGAT1 (0.49) | DGAT1 | |
| SCHEMBL34461780 | 0.78 | SCN10A (0.51) | ABL1MCHR1SCN10ASCN2A | |
| SCHEMBL31301527 | 0.74 | SCN10A (0.46) | ABL1SCN10ASCN2ALMNAMAPT | |
| SCHEMBL31301356 | 0.73 | PARP1 (0.44) | SCN10AMAPTTRPV1 | |
| SCHEMBL16420770 | 0.71 | ATR (0.66) | SCN10ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | DGAT1 1115/4885ABL1 524/4885MCHR1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.